EyeGate reports $4.1 million quarterly loss

EyeGate Pharmaceuticals reported a net loss of $4.1 million in the third quarter of 2017 compared with a net loss of $3.4 million in the same time period of 2016.
Revenues were down from $0.274 million in 2016’s third quarter to $0.075 million in the third quarter of 2017, according to a press release.
Research and development costs rose to $3.2 million in the quarter from $2.5 million in 2016’s third quarter, while general and administrative costs were down to $1 million from $1.2 million.
The company reported cash and (Read more...)

Full Story →